Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review)

National Cancer Institute: What is cancer? 2021, https://www.cancer.gov/about-cancer/understanding/what-is-cancer.

Blackadar CB: Historical review of the causes of cancer. World J Clin Oncol. 7:54–86. 2016. View Article : Google Scholar : PubMed/NCBI

Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK and Manyazewal T: New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 9:205031212110343662021. View Article : Google Scholar : PubMed/NCBI

Decker WK and Safdar A: Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev. 20:271–281. 2009. View Article : Google Scholar : PubMed/NCBI

Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, Zielinski C, Penninger JM, Kerjaschki D, Stingl G, et al: Paul Ehrlich (1854-1915) and his contributions to the foundation and birth of translational medicine. J Innate Immun. 8:111–120. 2016. View Article : Google Scholar : PubMed/NCBI

Rosenberg SA: IL-2: The first effective immunotherapy for human cancer. J Immunol. 192:5451–5458. 2014. View Article : Google Scholar : PubMed/NCBI

Pierpont TM, Limper CB and Richards KL: Past, present, and future of rituximab-the world's first oncology monoclonal antibody therapy. Front Oncol. 8:163. 2018. View Article : Google Scholar : PubMed/NCBI

June CH, O'Connor RS, Kawalekar OU, Ghassemi S and Milone MC: CAR T cell immunotherapy for human cancer. Science. 359:1361–1365. 2018. View Article : Google Scholar : PubMed/NCBI

Rosenberg SA, Restifo NP, Yang JC, Morgan RA and Dudley ME: Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008. View Article : Google Scholar : PubMed/NCBI

Gross G, Waks T and Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 86:10024–10028. 1989. View Article : Google Scholar : PubMed/NCBI

Graham C, Hewitson R, Pagliuca A and Benjamin R: Cancer immunotherapy with CAR-T cells-behold the future. Clin Med (Lond). 18:324–328. 2018. View Article : Google Scholar : PubMed/NCBI

Maus MV: A decade of CAR T cell evolution. Nat Cancer. 3:270–271. 2022. View Article : Google Scholar : PubMed/NCBI

Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, et al: Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 5:197ra1032013. View Article : Google Scholar : PubMed/NCBI

June CH, Riddell SR and Schumacher TN: Adoptive cellular therapy: A race to the finish line. Sci Transl Med. 7:280ps72015. View Article : Google Scholar : PubMed/NCBI

Lee YH and Kim CH: Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives. Arch Pharm Res. 42:607–616. 2019. View Article : Google Scholar : PubMed/NCBI

Titov A, Valiullina A, Zmievskaya E, Zaikova E, Petukhov A, Miftakhova R, Bulatov E and Rizvanov A: Advancing CAR T-cell therapy for solid tumors: Lessons learned from lymphoma treatment. Cancers (Basel). 12:1252020. View Article : Google Scholar : PubMed/NCBI

Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, Chen YY and Zhao W: CAR-T design: Elements and their synergistic function. EBioMedicine. 58:1029312020. View Article : Google Scholar : PubMed/NCBI

Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L, Momin N, Pishesha N, Rickelt S, Hynes RO and Ploegh H: Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci USA. 116:7624–7631. 2019. View Article : Google Scholar : PubMed/NCBI

Barber A, Rynda A and Sentman CL: Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol. 183:6939–6947. 2009. View Article : Google Scholar : PubMed/NCBI

Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS and Powell DJ Jr: High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia. 30:1355–1364. 2016. View Article : Google Scholar : PubMed/NCBI

Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, et al: The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens. J Immunother. 28:203–211. 2005. View Article : Google Scholar : PubMed/NCBI

Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC and Riddell SR: The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 3:125–135. 2015. View Article : Google Scholar

Zhang C, Liu J, Zhong JF and Zhang X: Engineering CAR-T cells. Biomark Res. 5:222017. View Article : Google Scholar : PubMed/NCBI

Sterner RC and Sterner RM: CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 11:692021. View Article : Google Scholar : PubMed/NCBI

Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P and Ganguly N: CAR T cell therapy: A new era for cancer treatment (Review). Oncol Rep. 42:2183–2195. 2019.PubMed/NCBI

Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G, Liu S and Ma J: CAR-T cell therapy in cancer: Tribulations and road ahead. J Immunol Res. 2020:19243792020. View Article : Google Scholar : PubMed/NCBI

Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al: Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 118:6050–6056. 2011. View Article : Google Scholar : PubMed/NCBI

Duong CP, Yong CS, Kershaw MH, Slaney CY and Darcy PK: Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Mol Immunol. 67:46–57. 2015. View Article : Google Scholar : PubMed/NCBI

Qian L, Li D, Ma L, He T, Qi F, Shen J and Lu XA: The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Cell Immunol. 304:49–54. 2016. View Article : Google Scholar : PubMed/NCBI

Lock D, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser T, Kolbe C, Al Rawashdeh W, Brauner J, Hardt O, et al: Automated manufacturing of potent CD20-directed chimeric antigen receptor t cells for clinical use. Hum Gene Ther. 28:914–925. 2017. View Article : Google Scholar : PubMed/NCBI

Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, Plotkin J and Sadelain M: Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 28:415–428. 2015. View Article : Google Scholar : PubMed/NCBI

Hombach A, Hombach AA and Abken H: Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target'activation and unintended initiation of an innate immune response. Gene Ther. 17:1206–1213. 2010. View Article : Google Scholar : PubMed/NCBI

Zhong XS, Matsushita M, Plotkin J, Riviere I and Sadelain M: Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 18:413–420. 2010. View Article : Google Scholar

Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, et al: Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology. 7:e14335182018. View Article : Google Scholar : PubMed/NCBI

Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, et al: A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther. 25:1003–1012. 2014. View Article : Google Scholar : PubMed/NCBI

Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM and Brenner MK: A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 12:933–941. 2005. View Article : Google Scholar : PubMed/NCBI

Beatty GL and Moon EK: Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology. 3:e9700272014. View Article : Google Scholar

Chmielewski M and Abken H: TRUCKs: The fourth generation of CARs. Expert Opin Biol Ther. 15:1145–1154. 2015. View Article : Google Scholar : PubMed/NCBI

Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE and Gilham DE: CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity. Mol Ther Oncolytics. 8:41–51. 2017. View Article : Google Scholar

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH and Darcy PK: Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 19:5636–5646. 2013. View Article : Google Scholar : PubMed/NCBI

Kim DW and Cho JY: Recent advances in allogeneic CAR-T cells. Biomolecules. 10:2632020. View Article : Google Scholar : PubMed/NCBI

Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD and Hirano N: A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 24:352–359. 2018. View Article : Google Scholar : PubMed/NCBI

Dai H, Wang Y, Lu X and Han W: Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 108:djv4392016. View Article : Google Scholar : PubMed/NCBI

Li D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, Yang X, Sun J, Li Z, Han WD and Wang W: Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther. 4:352019. View Article : Google Scholar : PubMed/NCBI

Levine BL, Miskin J, Wonnacott K and Keir C: Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 4:92–101. 2016. View Article : Google Scholar

Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S and Kobold S: Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 20:12832019. View Article : Google Scholar : PubMed/NCBI

Guo S and Deng CX: Effect of stromal cells in tumor microenvironment on metastasis initiation. Int J Biol Sci. 14:2083–2093. 2018. View Article : Google Scholar : PubMed/NCBI

Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, Anderson RT, Glogowska MJ, Estes P, Eagles JR, Le PN, et al: XactMice: Humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene. 35:290–300. 2016. View Article : Google Scholar

Najima Y, Tomizawa-Murasawa M, Saito Y, Watanabe T, Ono R, Ochi T, Suzuki N, Fujiwara H, Ohara O, Shultz LD, et al: Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood. 127:722–734. 2016. View Article : Google Scholar :

Yin L and Wang XJ, Chen DX, Liu XN and Wang XJ: Humanized mouse model: A review on preclinical applications for cancer immunotherapy. Am J Cancer Res. 10:4568–4584. 2020.

Zitvogel L, Pitt JM, Daillère R, Smyth MJ and Kroemer G: Mouse models in on immunology. Nat Rev Cancer. 16:759–773. 2016. View Article : Google Scholar : PubMed/NCBI

Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V, Krönke N, Feuerhake F, Ferreira de Figueiredo C, Blasczyk R, et al: CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol Ther Oncolytics. 18:504–524. 2020. View Article : Google Scholar : PubMed/NCBI

Jin CH, Xia J, Rafiq S, Huang X, Hu Z, Zhou X, Brentjens RJ and Yang YG: Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. EBioMedicine. 39:173–181. 2019. View Article : Google Scholar :

Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S, et al: Aberrant Lck signal via CD28 costimulation augments antigen-specific functionality and tumor control by redirected T cells with PD-1 blockade in humanized mice. Clin Cancer Res. 24:3981–3993. 2018. View Article : Google Scholar : PubMed/NCBI

Roskoski R Jr: The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014. View Article : Google Scholar

Szöőr Á, Tóth G, Zsebik B, Szabó V, Eshhar Z, Abken H and Vereb G: Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 484:1–8. 2020. View Article : Google Scholar

Liu Y, Zhou Y, Huang KH, Li Y, Fang X, An L, Wang F, Chen Q, Zhang Y, Shi A, et al: EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging (Albany NY). 11:11054–11072. 2019. View Article : Google Scholar : PubMed/NCBI

Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G and Fusco N: CAR-T cell therapy for triple-negative breast cancer and other solid tumors: Preclinical and clinical progress. Expert Opin Investig Drugs. 31:593–605. 2022. View Article : Google Scholar : PubMed/NCBI

Wei J, Sun H, Zhang A, Wu X, Li Y, Liu J, Duan Y, Xiao F, Wang H, Lv M, et al: A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers. Cell Immunol. 331:49–58. 2018. View Article : Google Scholar : PubMed/NCBI

Wallstabe L, Mades A, Frenz S, Einsele H, Rader C and Hudecek M: CAR T cells targeting α_vβ₃ integrin are effective against advanced cancer in preclinical models. Adv Cell Gene Ther. 1:e112018. View Article : Google Scholar

Zhao X, Qu J, Hui Y, Zhang H, Sun Y, Liu X, Zhao X, Zhao Z, Yang Q, Wang F and Zhang S: Clinicopathological and prognostic significance of c-Met overexpression in breast cancer. Oncotarget. 8:56758–56767. 2017. View Article : Google Scholar : PubMed/NCBI

Han Y, Xie W, Song DG and Powell DJ Jr: Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 11:922018. View Article : Google Scholar : PubMed/NCBI

Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J and Mukherjee P: CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol. 10:11492019. View Article : Google Scholar : PubMed/NCBI

Wallstabe L, Göttlich C, Nelke LC, Kühnemundt J, Schwarz T, Nerreter T, Einsele H, Walles H, Dandekar G, Nietzer SL and Hudecek M: ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight. 4:e1263452019. View Article : Google Scholar : PubMed/NCBI

Zhao Z, Li Y, Liu W and Li X: Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer. Biomed Res Int. 2020:47951712020.PubMed/NCBI

Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, Cenciarelli C, Venditti A, Del Principe MI, Lauro D, et al: In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. Int J Cancer. 146:236–247. 2020. View Article : Google Scholar

Song DG, Ye Q, Poussin M, Chacon JA, Figini M and Powell DJ Jr: Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol. 9:562016. View Article : Google Scholar : PubMed/NCBI

Seitz CM, Schroeder S, Knopf P, Krahl AC, Hau J, Schleicher S, Martella M, Quintanilla-Martinez L, Kneilling M, Pichler B, et al: GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 9:16833452019. View Article : Google Scholar

Yang Y, Vedvyas Y, McCloskey JE, Min IM and Jin MM: ICAM-1 targeting CAR T cell therapy for triple negative breast cancer. Cancer Res. 79(13 Suppl): S23222019. View Article : Google Scholar

Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, Ma X and Wei F: CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother. 68:365–377. 2019. View Article : Google Scholar

Petrovic K, Robinson J, Whitworth K, Jinks E, Shaaban A and Lee SP: TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo. PLoS One. 14:e02240152019. View Article : Google Scholar : PubMed/NCBI

Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, et al: TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. Cancer Res. 78:489–500. 2018. View Article : Google Scholar :

Bedoya DM, King T and Posey AD: Generation of CART cells targeting oncogenic TROP2 for the elimination of epithelial malignancies. Cytotherapy. 21(Suppl): S11–S12. 2019. View Article : Google Scholar

National Library of Medicine (NLM): Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma. ClinicalTrials.gov ID, NCT02208362. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/study/NCT02208362.

National Library of Medicine (NLM): CART-EGFRvIII + Pembrolizumab in GBM. ClinicalTrials.gov ID, NCT03726515. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03726515.

National Library of Medicine (NLM): GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression. ClinicalTrials.gov ID, NCT03198546. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03198546.

National Library of Medicine (NLM): Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma. ClinicalTrials.gov ID, NCT00902044. NLM; Bethesda, MD: 2010, https://clinicaltrials.gov/ct2/show/NCT00902044.

National Library of Medicine (NLM): CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells (HITM). ClinicalTrials.gov ID, NCT01373047. NLM; Bethesda, MD: 2011, https://clinicaltrials.gov/ct2/show/NCT01373047.

National Library of Medicine (NLM): Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer. ClinicalTrials.gov ID, NCT01897415. NLM; Bethesda, MD: 2013, https://clinicaltrials.gov/ct2/show/NCT01897415.

National Library of Medicine (NLM): CAR T Cell Immunotherapy for Pancreatic Cancer. ClinicalTrials.gov ID, NCT03323944. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03323944.

National Library of Medicine (NLM): Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma. ClinicalTrials.gov ID, NCT03159819. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03159819.

National Library of Medicine (NLM): Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma. ClinicalTrials.gov ID, NCT03393936. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03393936.

National Library of Medicine (NLM): PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer. ClinicalTrials.gov ID, NCT03873805. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03873805.

National Library of Medicine (NLM): CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer. ClinicalTrials.gov ID, NCT03089203. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03089203.

National Library of Medicine (NLM): Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*). ClinicalTrials.gov ID, NCT04020575. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04020575.

National Library of Medicine (NLM): MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. ClinicalTrials.gov ID, NCT03585764. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03585764.

National Library of Medicine (NLM): Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors. ClinicalTrials.gov ID, NCT02498912. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02498912.

National Library of Medicine (NLM): T-Cell Therapy for Advanced Breast Cancer. ClinicalTrials.gov ID, NCT02792114. NLM; Bethesda, MD: 2016, https://clinicaltrials.gov/ct2/show/NCT02792114.

National Library of Medicine (NLM): T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR). ClinicalTrials.gov ID, NCT02442297. NLM; Bethesda, MD: 2016, https://clinicaltrials.gov/ct2/show/NCT02442297.

National Library of Medicine (NLM): HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases. ClinicalTrials.gov ID, NCT03696030. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03696030.

National Library of Medicine (NLM): Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin. ClinicalTrials.gov ID, NCT02414269. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02414269.

National Library of Medicine (NLM): Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19. ClinicalTrials.gov ID, NCT01044069. NLM; Bethesda, MD: 2010, https://clinicaltrials.gov/ct2/show/NCT01044069.

National Library of Medicine (NLM): Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19. ClinicalTrials.gov ID, NCT00466531. NLM; Bethesda, MD: 2007, https://clinicaltrials.gov/ct2/show/NCT00466531.

National Library of Medicine (NLM): CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (CRETI-NH). ClinicalTrials.gov ID, NCT00586391. NLM; Bethesda, MD: 2009, https://clinicaltrials.gov/ct2/show/NCT00586391.

National Library of Medicine (NLM): CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (CRETI-NH). ClinicalTrials.gov ID, NCT00608270. NLM; Bethesda, MD: 2009, https://clinicaltrials.gov/ct2/show/NCT00608270.

National Library of Medicine (NLM): Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies. ClinicalTrials.gov ID, NCT02315612. NLM; Bethesda, MD: 2014, https://clinicaltrials.gov/ct2/show/NCT02315612.

National Library of Medicine (NLM): Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma. ClinicalTrials.gov ID, NCT01722149. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT01722149.

National Library of Medicine (NLM): Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01. ClinicalTrials.gov ID, NCT02311621. NLM; Bethesda, MD: 2014, https://clinicaltrials.gov/ct2/show/NCT02311621.

National Library of Medicine (NLM): Study of bb21217 in Multiple Myeloma. ClinicalTrials.gov ID, NCT03274219. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03274219.

National Library of Medicine (NLM): Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL). ClinicalTrials.gov ID, NCT00881920. NLM; Bethesda, MD: 2009, https://clinicaltrials.gov/ct2/show/NCT00881920.

National Library of Medicine (NLM): KSafety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA). ClinicalTrials.gov ID, NCT03939026. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03939026.

National Library of Medicine (NLM): Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL. ClinicalTrials.gov ID, NCT03666000. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03666000.

National Library of Medicine (NLM): A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON). ClinicalTrials.gov ID, NCT04035434. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04035434.

National Library of Medicine (NLM): Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMELI-01). ClinicalTrials.gov ID, NCT03190278. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03190278.

National Library of Medicine (NLM): Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL). ClinicalTrials.gov ID, NCT04093596. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04093596.

National Library of Medicine (NLM): SaalloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK). ClinicalTrials.gov ID, NCT03692429. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03692429.

National Library of Medicine (NLM): Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC). ClinicalTrials.gov ID, NCT01140373. NLM; Bethesda, MD: 2010, https://clinicaltrials.gov/ct2/show/NCT01140373.

National Library of Medicine (NLM): 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (GRAIN). ClinicalTrials.gov ID, NCT01822652. NLM; Bethesda, MD: 2013, https://clinicaltrials.gov/ct2/show/NCT01822652.

National Library of Medicine (NLM): iC9-GD2-CARVZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (VEGAS). ClinicalTrials.gov ID, NCT01953900. NLM; Bethesda, MD: 2014, https://clinicaltrials.gov/ct2/show/NCT01953900.

Almond LM, Charalampakis M, Ford SJ, Gourevitch D and Desai A: Myeloid sarcoma: Presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 17:263–267. 2017. View Article : Google Scholar : PubMed/NCBI

Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, et al: Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 25:285–295. 2017. View Article : Google Scholar : PubMed/NCBI

Jain MD, Bachmeier CA, Phuoc VH and Chavez JC: Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. Ther Clin Risk Manag. 14:1007–1017. 2018. View Article : Google Scholar : PubMed/NCBI

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, et al: Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet. 396:839–852. 2020. View Article : Google Scholar : PubMed/NCBI

Abbott RC, Cross RS and Jenkins MR: Finding the keys to the CAR: Identifying novel target antigens for T cell redirection immunotherapies. Int J Mol Sci. 21:5152020. View Article : Google Scholar : PubMed/NCBI

Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, et al: Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 44:1444–1454. 2016. View Article : Google Scholar : PubMed/NCBI

Li X, Ding Y, Zi M, Sun L, Zhang W, Chen S and Xu Y: CD19, from bench to bedside. Immunol Lett. 183:86–95. 2017. View Article : Google Scholar : PubMed/NCBI

Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al: Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 33:16882015. View Article : Google Scholar : PubMed/NCBI

Cortesi L, Rugo HS and Jackisch C: An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 16:255–282. 2021. View Article : Google Scholar : PubMed/NCBI

Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha, Behl T, Jha SK and Tang H: Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 22:1052023. View Article : Google Scholar : PubMed/NCBI

Schoninger SF and Blain SW: The ongoing search for biomarkers of CDK4/6 inhibitor responsiveness in breast cancer. Mol Cancer Ther. 19:3–12. 2020. View Article : Google Scholar : PubMed/NCBI

Martorana F, Motta G, Pavone G, Motta L, Stella S, Vitale SR, Manzella L and Vigneri P: AKT inhibitors: New weapons in the fight against breast cancer? Front Pharmacol. 12:6622322021. View Article : Google Scholar : PubMed/NCBI

Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF and Schiff R: Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 17:233–250. 2020. View Article : Google Scholar

Tóth G, Szöllősi J, Abken H, Vereb G and Szöőr Á: A small number of HER2 redirected CAR T cells significantly improves immune response of adoptively transferred mouse lymphocytes against human breast cancer xenografts. Int J Mol Sci. 21:10392020. View Article : Google Scholar : PubMed/NCBI

Toulouie S, Johanning G and Shi Y: Chimeric antigen receptor T-cell immunotherapy in breast cancer: Development and challenges. J Cancer. 12:1212–1219. 2021. View Article : Google Scholar : PubMed/NCBI

Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI

Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:4285–4289. 1992. View Article : Google Scholar : PubMed/NCBI

Bou-Dargham MJ, Draughon S, Cantrell V, Khamis ZI and Sang QA: Advancements in human breast cancer targeted therapy and immunotherapy. J Cancer. 12:6949–6963. 2021. View Article : Google Scholar : PubMed/NCBI

Rivas SR, Valdez MJM, Govindarajan V, Seetharam D, Doucet-O'Hare TT, Heiss JD and Shah AH: The role of HERV-K in cancer stemness. Viruses. 14:20192022. View Article : Google Scholar : PubMed/NCBI

Zhao J, Rycaj K, Geng S, Li M, Plummer JB, Yin B, Liu H, Xu X, Zhang Y, Yan Y, et al: Expression of human endogenous retrovirus type K envelope protein is a novel candidate prognostic marker for human breast cancer. Genes Cancer. 2:914–922. 2011. View Article : Google Scholar

Pegram M and Slamon D: Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 27(Suppl 9): S13–S19. 2000.

Walsh EM, Keane MM, Wink DA, Callagy G and Glynn SA: Review of triple negative breast cancer and the impact of inducible nitric oxide synthase on tumor biology and patient outcomes. Crit Rev Oncog. 21:333–351. 2016. View Article : Google Scholar : PubMed/NCBI

Tsutsui S, Ohno S, Murakami S, Hachitanda Y and Oda S: Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat. 71:67–75. 2002. View Article : Google Scholar : PubMed/NCBI

Nasiri F, Kazemi M, Mirarefin SMJ, Mahboubi Kancha M, Ahmadi Najafabadi M, Salem F, Dashti Shokoohi S, Evazi Bakhshi S and Safarzadeh Kozani P and Safarzadeh Kozani P: CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. Front Immunol. 13:10187862022. View Article : Google Scholar : PubMed/NCBI

Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, et al: PARP inhibitor efficacy depends on CD8⁺ T-cell recruitment via intratumoral sting pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9:722–737. 2019. View Article : Google Scholar : PubMed/NCBI

Ternette N, Olde Nordkamp MJM, Müller J, Anderson AP, Nicastri A, Hill AVS, Kessler BM and Li D: Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens. Proteomics. 18:17004652018. View Article : Google Scholar : PubMed/NCBI

National Library of Medicine (NLM): Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection. ClinicalTrials.gov ID, NCT04164615. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04164615.

National Library of Medicine (NLM): Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer. ClinicalTrials.gov ID, NCT04329065. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04329065.

National Library of Medicine (NLM): Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab. ClinicalTrials.gov ID, NCT04276493. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04276493.

National Library of Medicine (NLM): Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection. ClinicalTrials.gov ID, NCT04170595. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04170595.

National Library of Medicine (NLM): A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases. ClinicalTrials.gov ID, NCT03500380. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03500380.

National Library of Medicine (NLM): Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2. ClinicalTrials.gov ID, NCT00019812. NLM; Bethesda, MD: 2003, https://clinicaltrials.gov/ct2/show/NCT00019812.

National Library of Medicine (NLM): Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT00003539. NLM; Bethesda, MD: 2004, https://clinicaltrials.gov/ct2/show/NCT00003539.

National Library of Medicine (NLM): Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT00006228. NLM; Bethesda, MD: 2003, https://clinicaltrials.gov/ct2/show/NCT00006228.

National Library of Medicine (NLM): Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2. ClinicalTrials.gov ID, NCT00003992. NLM; Bethesda, MD: 2004, https://clinicaltrials.gov/ct2/show/NCT00003992.

National Library of Medicine (NLM): Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02). ClinicalTrials.gov ID, NCT03571633. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03571633.

National Library of Medicine (NLM): A Study of Pertuzumab in Participants With Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT02491892. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02491892.

National Library of Medicine (NLM): Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab. ClinicalTrials.gov ID, NCT00301899. NLM; Bethesda, MD: 2006, https://clinicaltrials.gov/ct2/show/NCT00301899.

National Library of Medicine (NLM): A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT04924699. NLM; Bethesda, MD: 2021, https://clinicaltrials.gov/ct2/show/NCT04924699.

National Library of Medicine (NLM): ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03). ClinicalTrials.gov ID, NCT04829604. NLM; Bethesda, MD: 2021, https://clinicaltrials.gov/ct2/show/NCT04829604.

National Library of Medicine (NLM): Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour. ClinicalTrials.gov ID, NCT04107142. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04107142.

National Library of Medicine (NLM): A Study to Investigate LYL797 in Adults With Solid Tumors. ClinicalTrials.gov ID, NCT05274451. NLM; Bethesda, MD: 2022, https://clinicaltrials.gov/ct2/show/NCT05274451.

National Library of Medicine (NLM): A Biomarker Screening Protocol for Participants With Solid Tumors (START). ClinicalTrials.gov ID, NCT05891197. NLM; Bethesda, MD: 2023, https://clinicaltrials.gov/ct2/show/NCT05891197.

National Library of Medicine (NLM): cMet CAR RNA T Cells Targeting Breast Cancer. ClinicalTrials.gov ID, NCT01837602. NLM; Bethesda, MD: 2013, https://clinicaltrials.gov/ct2/show/NCT01837602.

National Library of Medicine (NLM): Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso. ClinicalTrials.gov ID, NCT02580747. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02580747.

National Library of Medicine (NLM): Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor. ClinicalTrials.gov ID, NCT02587689. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02587689.

National Library of Medicine (NLM): Multi-4SCAR-T Therapy Targeting Breast Cancer. ClinicalTrials.gov ID, NCT04430595. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04430595.

National Library of Medicine (NLM): EpCAM CAR-T for Treatment of Advanced Solid Tumors. ClinicalTrials.gov ID, NCT02915445. NLM; Bethesda, MD: 2016, https://clinicaltrials.gov/ct2/show/NCT02915445.

National Library of Medicine (NLM): C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N). ClinicalTrials.gov ID, NCT03635632. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03635632.

Bonifant CL, Jackson HJ, Brentjens RJ and Curran KJ: Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 3:160112016. View Article : Google Scholar : PubMed/NCBI

Almåsbak H, Aarvak T and Vemuri MC: CAR T cell therapy: A game changer in cancer treatment. J Immunol Res. 2016:54746022016. View Article : Google Scholar : PubMed/NCBI

Abreu TR, Fonseca NA, Gonçalves N and Moreira JN: Current challenges and emerging opportunities of CAR-T cell therapies. J Control Release. 319:246–261. 2020. View Article : Google Scholar : PubMed/NCBI

Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH and Sherwin SA: Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 5:222017. View Article : Google Scholar : PubMed/NCBI

Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B, et al: Management of cytokine release syndrome related to CAR-T cell therapy. Front Med. 13:610–617. 2019. View Article : Google Scholar : PubMed/NCBI

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 124:188–195. 2014. View Article : Google Scholar : PubMed/NCBI

Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, et al: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 121:5154–5157. 2013. View Article : Google Scholar : PubMed/NCBI

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet. 385:517–528. 2015. View Article : Google Scholar

Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119:2709–2720. 2012. View Article : Google Scholar :

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 5:177ra382013. View Article : Google Scholar : PubMed/NCBI

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 368:1509–1518. 2013. View Article : Google Scholar : PubMed/NCBI

Curran KJ, Pegram HJ and Brentjens RJ: Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions. J Gene Med. 14:405–415. 2012. View Article : Google Scholar : PubMed/NCBI

Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G and Oosterwijk E: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol. 24:e20–e22. 2006. View Article : Google Scholar : PubMed/NCBI

Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851. 2010. View Article : Google Scholar : PubMed/NCBI

Marin V, Cribioli E, Philip B, Tettamanti S, Pizzitola I, Biondi A, Biagi E and Pule M: Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods. 23:376–386. 2012. View Article : Google Scholar : PubMed/NCBI

Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, Cote DJ, Spendley L, Kim AH, Robertson MS, et al: Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 142:1334–1348. 2019. View Article : Google Scholar : PubMed/NCBI

Miao L, Zhang Z, Ren Z and Li Y: Reactions related to CAR-T cell therapy. Front Immunol. 12:6632012021. View Article : Google Scholar : PubMed/NCBI

Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M and June CH: T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 1:26–31. 2013. View Article : Google Scholar

Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, et al: Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70:9053–9061. 2010. View Article : Google Scholar : PubMed/NCBI

Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH and Grupp SA: Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther. 22:1575–1586. 2011. View Article : Google Scholar : PubMed/NCBI

Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI

Lindau D, Gielen P, Kroesen M, Wesseling P and Adema GJ: The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 138:105–115. 2013. View Article : Google Scholar :

Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA and Kang CY: Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: An alternative cell-based antitumor vaccine. J Immunol. 182:1818–1828. 2009. View Article : Google Scholar : PubMed/NCBI

Davis RJ, Van Waes C and Allen CT: Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 58:59–70. 2016. View Article : Google Scholar : PubMed/NCBI

Fedorov VD, Themeli M and Sadelain M: PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 5:215ra1722013. View Article : Google Scholar : PubMed/NCBI

Chmielewski M, Kopecky C, Hombach AA and Abken H: IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71:5697–5706. 2011. View Article : Google Scholar : PubMed/NCBI

Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M and Brentjens RJ: Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 119:4133–4141. 2012. View Article : Google Scholar : PubMed/NCBI

Patel U, Abernathy J, Savani BN, Oluwole O, Sengsayadeth S and Dholaria B: CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem. 3(Suppl 1): S24–S31. 2022. View Article : Google Scholar

Włodarczyk M and Pyrzynska B: CAR-NK as a rapidly developed and efficient immunotherapeutic strategy against cancer. Cancers (Basel). 15:1172022. View Article : Google Scholar

Hawkins ER, D'Souza RR and Klampatsa A: Armored CAR T-cells: The next chapter in T-cell cancer immunotherapy. Biologics. 15:95–105. 2021.PubMed/NCBI

Rafiq S, Hackett CS and Brentjens RJ: Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 17:147–167. 2020. View Article : Google Scholar :

Xia L, Zheng Z, Liu JY, Chen YJ, Ding J, Hu GS, Hu YH, Liu S, Luo WX, Xia NS and Liu W: Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition. Cancer Immunol Res. 9:707–722. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, Liu X, Lv Z, Yang P, Xu W, et al: Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 20:1262021. View Article : Google Scholar : PubMed/NCBI

Yan T, Zhu L and Chen J: Current advances and challenges in CAR T-Cell therapy for solid tumors: Tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 12:142023. View Article : Google Scholar : PubMed/NCBI

Collins DC, Sundar R, Lim JSJ and Yap TA: Towards precision medicine in the clinic: From biomarker discovery to novel therapeutics. Trends Pharmacol Sci. 38:25–40. 2017. View Article : Google Scholar